EUCTR2006-005364-65-AT进行中（未招募）不适用
Intermittent Treatment with Taxotere and Prednisone in patients with asymptomatic, hormone-refractory prostate cancer: A Multicenter Phase II Trial - TOPAS
AUO0 个研究点开始时间: 2007年4月25日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •- Histologically proven adenocarcinoma of the prostate
- •- Hormone refractory prostate cancer with or without metastases after definitive treatment of the primary tumor, either radical prostatectomy or definitive radiotherapy of the prostate, defined as progression under prior hormonal treatment with LH-RH analogues or orchiectomy and anti-androgens, given either together or consecutively
- •- Irradiation of the tumor-bed allowed
- •- Progressive disease, defined as PSA progression documented by 2 increased PSA values over a previous reference value or measurable disease progression according to the modRECIST criteria
- •- PSA at time of study entry > 5 ng/ml (hybritech or equivalent, normal lab upper value 4 ng/ml) within 1 week prior to randomisation and < 40 ng/ml.
- •- Age =18 years
- •- WHO Performance status 0-2
- •- No tumor-related symptoms
- •- Stable analgesic use is allowed
- •- Anti-androgen treatment with Flutamide, Bicalutamide or Nilutamide should be withdrawn at least 6 weeks prior to the start of chemotherapy
- •- Continuation of bisphosphonates allowed
- •- Castrate level of testosterone (< 0.5 ng/ml). Patients with medical castration with LH-RH analogue must continue LH-RH analogue.
- •- Adequate haematological functions:
- •Hb = 10 g/dl; WBC = 3.500 x109/l; ANC = 1,5 x109/l; platelets = 100 x109/l.
- •- Adequate liver function:
- •Bilirubin = 1,5 x UNL (upper normal level); ASAT and ALAT = 1,5 x UNL.
- •- Before patient registration / randomization, written informed consent must be given according to ICH-GCP, and national / local regulations
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Evidence of brain metastases.
- •- Painful and/or destructive bone metastases for which radiation therapy, bisphosphonates or bone-seeking radionucleides are considered necessary by the treating physician.
- •- Unequivocal tumor-related symptoms.
- •- Increasing analgesic use, unstable pain.
- •- Prior treatment with chemotherapy, bone-seeking radionucleides or radiotherapy involving more than 25% of bone marrow producing area. (Prior use of Estramustine phosphate and/or bisphosphonates are allowed.)
- •- Active infection or known HIV.
- •- History of interstitial pneumonitis or pulmonary fibrosis.
- •- Pre-existing neuropathy (PNP = G1).
- •- Second primary cancer (except adequately treated superficial cancers e.g. superficial urothelial cancer or in situ carcinomas, skin cancer and melanoma without signs of recurrence in the past 5 years).
- •- Concurrent treatment with other experimental drugs or anti-cancer drugs (except LH-RH agonist).
- •- Any condition / concomitant disease not allowing chemotherapy with docetaxel and prednisone from an internal medicine point of view. (Renal insufficiency requiring dialyses; congestive heart failure or uncontrolled angina pectoris; prior myocardial infarction within 6 months of start of chemotherapy; uncontrolled hypertension or arrhythmias; dementia; instable diabetes mellitus, ulceration from diabetes mellitus or other conditions not allowing high dose corticosteroids; effusions in pericardium, pleura or abdomen symptomatic and in need of being punctured.
- •- Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
研究者
相似试验
招募中
不适用
Combination Therapy with Tiotropium in Chronic Obstructive Pulmonary Disease (COTTS)ACTRN12608000079347Centre for Clinical Research and effective practice (CCRep)40
进行中（未招募）
不适用
A Pilot Study of Taxotere (Docetaxel), Cisplatin and 5FU (TPF) in the Palliative Treatment of Squamous Cell Carcinoma of the Head and Neck - tinpatocally recurrent or metastatic squamous call carcinoma of the head and neckEUCTR2006-005816-29-GBRoyal Wolverhampton Hospitals Trust25
进行中（未招募）
不适用
A Pilot Phase II combination study of Taxotere (Docetaxel) and Erbitux (Cetuximab) as a NEOadjuvant therapy in patients with triple-negative” (HR and Her2 negative) operable breast cancer. TENEO Study - TENEO studyCancer du sein opérable RH- et Her2-, en situation néoadjuvanteMedDRA version: 9.1Level: LLTClassification code 10022882Term: Invasive ductal breast cancerEUCTR2007-002371-13-FRCentre Jean Perrin
已完成
不适用
Combination therapy with tiotopium and indacaterol in patients with COPDChronic obstructive pulmonary disease (COPD)JPRN-UMIN000011958Hamamatsu University School of Medicine80
已完成
不适用
A Randomised Trial of Adriamycin and Taxotere vs. Adriamycin and Cyclophosphamide in Breast CancerMalignant neoplasm of breastBreast cancerCancerISRCTN15113276Scottish Cancer Therapy Network (UK)363